Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11829508 | 0.81 | BCL6 (0.53) | BCL6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL12203607 | 0.80 | KMT2A (0.61) | ALDH1A1MAPTHPGDKMT2ANPC1 | |
| SCHEMBL15510403 | 0.80 | MAPT (0.74) | KDM4EALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL6614923 | 0.80 | NAMPT (0.58) | BCL6KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL11156215 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL1233811 | 0.80 | BCL6 (0.62) | BCL6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL11828701 | 0.78 | BCL6 (0.69) | BCL6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL6612030 | 0.78 | NAMPT (0.62) | ALDH1A1NPC1 | |
| SCHEMBL11830230 | 0.78 | BCL6 (0.57) | BCL6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL14031230 | 0.77 | MAPT (0.61) | BCL6KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115620-B2 | 1,3-disubstituted-2-thioxo-imidazolidine-4,5-diones as potassium channel openers | WYETH (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030119890-A1 | 1,3-Disubstituted-2-thioxo-imidazolidine-4,5-diones as potassium channel openers | WYETH (US) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119890-A1 | 1,3-Disubstituted-2-thioxo-imidazolidine-4,5-diones as potassium channel openers | KCNJ2, KCNJ1, KCNN1 | BCL6 2729/4885KDM4E 1433/4885ALDH1A1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.